Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs, Inc. filings document the regulatory record for an NYSE-listed digital manufacturing company that produces custom parts for prototyping, testing, bridge production, short-run production, and end-use applications. Its SEC disclosures cover operating results, revenue by service activity, non-GAAP measures, cash-flow commentary, and business updates related to CNC machining, digital platforms, and manufacturing capacity.
PRLB filings also include Form 8-K material-event reports for earnings releases and executive leadership changes, amendments to previously furnished results information, and proxy materials covering board matters, executive compensation, equity awards, shareholder voting items, and governance. The company’s filings identify its common stock under the PRLB ticker on the New York Stock Exchange.
Proto Labs Inc reported that Chief Commercial Officer Bernardo Parlange received new equity compensation. He was granted 2,109 shares of common stock as restricted stock units, plus options on 3,789 shares of common stock at an exercise price of $71.13 per share. The RSUs and the underlying shares from the option grant vest in four equal annual installments, with 25% vesting on May 20, 2027 and on each May 20 thereafter until fully vested. Following these awards, the filing shows 2,109 common shares and options for 3,789 shares held directly.
Proto Labs Inc filed an initial Form 3 for Bernardo Parlange, who serves as Chief Commercial Officer. This filing is a baseline statement of his beneficial ownership position as an officer and does not report any stock transactions or changes in holdings.
Black Archie C. reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Archie C. Black received an equity award of 2,210 deferred stock units on Common Stock. These units were granted at no cash cost and increase his direct holdings to 28,428 shares. The units vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Shareholders, and must be retained until his service on the Board of Directors ends.
Chand Sujeet reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Sujeet Chand received an award of 2,210 shares of Common Stock as a grant with no cash price per share. These are deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders.
The units must be retained until Chand’s service on the company’s Board of Directors ends, underscoring their role as long-term director compensation. After this award, Chand directly holds 26,863 shares of Proto Labs common stock.
Proto Labs Inc director Moonhie Chin acquired 2,210 shares of common stock as a stock award. The Form 4 shows this equity grant at a price of $0.0000 per share on May 19, 2026, increasing Chin’s direct holdings to 22,306 shares.
The footnote explains these are deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the Company’s 2027 Annual Meeting of Shareholders, and must be retained until Chin’s service on the Board of Directors ends.
Gawlick Rainer reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Rainer Gawlick received an award of 2,210 deferred stock units tied to common stock. The units were granted at no cash cost and increase his direct holdings to 46,093 common shares and units.
The deferred stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders, but must be retained until his service on the Board of Directors ends. This filing reflects routine, compensation-related equity, not an open-market purchase or sale.
WEHRWEIN SVEN reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Sven Wehrwein received an equity award of 2,210 deferred stock units on Common Stock. The award was granted at no cash cost per share and is a form of board compensation rather than an open-market purchase.
These deferred stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders, and must be held until his service on the Board of Directors ends. Following this grant, Wehrwein directly holds 34,505 shares of Proto Labs common stock.
Proto Labs director Donald G. Krantz reported an acquisition of company stock through a compensation grant. He received 2,210 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share, reflecting an equity award rather than a market purchase.
These restricted stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders. After this award, Krantz directly holds 26,863 shares of Proto Labs common stock.
Proto Labs, Inc. reported the results of its Annual Meeting of Shareholders. Investors approved an amendment to the Amended and Restated 2022 Long-Term Incentive Plan, adding 395,000 shares available for equity awards to employees and directors.
Shareholders elected all seven board nominees, ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and supported executive compensation in an advisory vote. They also chose an annual frequency for future advisory votes on executive pay.
Proto Labs Inc: Schedule 13G/A amendment showing a passive investor position. Disciplined Growth Investors, Inc. reports beneficial ownership of 2,497,355 shares of Proto Labs common stock, representing 10.5% of the class as of 03/31/2026. The filing lists 2,351,815 shares with sole voting power and 2,497,355 shares with sole dispositive power.